Advent International has completed an acquisition of Sanofi’s European generics business Zentiva.
Worth €1.9bn ($2.2bn), the acquisition follows a share purchase agreement signed by Sanofi and Advent in June 2018.
Go deeper with GlobalData
Advent is a private equity firm that is based in the US, while Sanofi is a France-based pharmaceutical company.
The divestment is in line with Sanofi’s strategy to simplify and reshape its business.
Roche has announced an acquisition of Tusk Therapeutics for €655m ($759m).
As part of the deal, Roche intends to make an upfront payment of €70m ($81.8m) and contingent payments of up to €585m ($684m) upon achieving pre-determined milestones.
The acquisition will add Tusk Therapeutics’ interleukin-2 (IL-2) cytokine signal preserving, anti-interleukin-2 receptor alpha chain (CD25) antibody to its product portfolio. The antibody is designed to minimise regulatory T-cells that suppress immune response.
After the acquisition, Roche will continue to develop the antibody, while Black Belt Therapeutics (a spin out of Tusk therapeutics) will develop the rest of Tusks’ product portfolio.
Clinigen Group has completed a previously announced acquisition of CSM Parent.
Based in the UK, Clinigen is a pharmaceutical and services company, while CSM Parent is a US-based services company.
PCI Pharma Services has completed an acquisition of Sherpa Clinical Packaging.
Sherpa’s services are expected to be a complementary addition to PCI’s offerings, allowing the company to provide better services to existing and new customers. It also adds manufacturing and packaging plants across eight locations worldwide.
The acquisition of Sherpa follows an acquisition of Pharmaceutical Packaging Professionals in February 2018 that provided PCI with direct access to the Australian market.
Based in the US, PCI Pharma is a pharmaceutical outsourcing services provider, while Sherpa is a clinical services provider.
Goodwin Procter was appointed as the legal adviser to PCI for the acquisition, Alvarez & Marsal was engaged to render due diligence services.
